Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | AR | P10275 | 10/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30166195 | 1.00 | TSHR (0.60) | TSHRARALDH1A1MCL1CYP1A2 | |
| Hydrochloric Acid SCHEMBL28845702 | 0.98 | TSHR (0.58) | TSHRARALDH1A1MCL1CYP1A2 | |
| SCHEMBL11099454 | 0.88 | TSHR (0.52) | TSHRARALDH1A1SLC22A12DYRK1A | |
| SCHEMBL3237062 | 0.83 | TSHR (0.46) | TSHRARALDH1A1MCL1DYRK1A | |
| SCHEMBL29941499 | 0.81 | TSHR (0.65) | TSHRARALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL102574 | 0.81 | TSHR (0.65) | TSHRARALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL9715679 | 0.79 | AR (0.46) | TSHRARALDH1A1 | |
| Hydrochloric Acid SCHEMBL20840273 | 0.79 | TSHR (0.62) | TSHRARALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL5498981 | 0.78 | AR (0.50) | TSHRARSLC22A12 | |
| SCHEMBL16950511 | 0.77 | TSHR (0.38) | TSHRALDH1A1CYP1A2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104188971-B | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | 配体药物公司 | 2017-05-03 | — | — | CN | claimed |
| EP-0657430-B1 | Isopropyl-(2-methoxyethyl)-4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-piridine-3,5-dicarboxylate | BAYER AG (DE) | 1999-06-02 | — | — | EP | claimed |
| EP-0657430-A1 | Isopropyl-(2-methoxyethyl)-4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-piridine-3,5-dicarboxylate | BAYER AG (DE) | 1995-06-14 | — | — | EP | claimed |
| CN-115380030-B | N-heteroarylalkyl-2- (heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2025-05-16 | — | — | CN | disclosed |
| CN-117580839-A | Anti-cancer nuclear hormone receptor targeting compounds | 诺维逊生物股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-3515916-B1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| WO-2023011608-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海枢境生物科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| EP-4126848-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-115380030-A | N-heteroarylalkyl-2- (heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2022-11-22 | — | — | CN | disclosed |
| WO-2021202781-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-07 | — | — | WO | disclosed |
| WO-1996025426-A9 | NOVEL DIPEPTIDE AMIDINES AS THROMBIN INHIBITORS | — | 1997-06-12 | — | — | WO | disclosed |
| US-5633384-A | FROM O-ALKYLTHIOBENZONITRILES | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1997-05-27 | — | — | US | disclosed |
| EP-0702008-A2 | Method for producing 1,2-benzisothiazol-3-ones | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 1996-03-20 | — | — | EP | disclosed |
| EP-0657430-A1 | Isopropyl-(2-methoxyethyl)-4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-piridine-3,5-dicarboxylate | BAYER AG (DE) | 1995-06-14 | — | — | EP | disclosed |
| US-5124342-A | Antiinflammatory, antiarthritic agents; antiallergens; skin disorders | ABBOTT LABORATORIES (US) | 1992-06-23 | — | — | US | disclosed |
| EP-0457803-A4 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | — | 1991-12-04 | — | — | EP | disclosed |
| EP-0457803-A1 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | ABBOTT LABORATORIES (US) | 1991-11-27 | — | — | EP | disclosed |
| WO-1990009801-A1 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | ABBOTT LABORATORIES (US) | 1990-09-07 | — | — | WO | disclosed |
| WO-1990009381-A1 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | ABBOTT LABORATORIES (US) | 1990-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | SSTR4, SSTR3, SSTR5 | TSHR 33/4885AR 358/4885ALDH1A1 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.